Healthcare
Live Price
Offline$10.25
+0.89% today
1Y Change
-61.25%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Perrigo Company plc (PRGO) is a Healthcare stock with a market cap of $1.64B and listed on NYSE. The stock last traded around $10.25 and down 61.2% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -2.8%, EPS growth of -723.2%, a dividend yield of 9.7%. What stands out right now is revenue -2.8%, EPS -723.2%, free cash flow -40.7% with operating margin 5.9% and ROIC 3.3%. The dividend matters to the case here, with a current yield around 9.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PRGO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRGO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PRGO Max Drawdown
-67.46%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PRGO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$4.3B
-2.8% YoY
FY Net Income
-$1.4B
-729.7% YoY
Free Cash Flow
$145.1M
-40.7% YoY
Revenue Growth
-2.8%
EPS Growth
-723.2%
Gross Margin
35.1%
Net Margin
-33.5%
Income statement
USD
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | 4.1B | 4.5B | 4.7B | 4.4B | 4.3B |
| Gross Profit | 1.4B | 1.5B | 1.7B | 1.5B | 1.5B |
| Operating Income | 600M | 121M | 284M | 312M | 313M |
| EBITDA | 886M | 407M | 654M | 639M | 637M |
| Net Income | -69M | -141M | -13M | -172M | -1.4B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.9B | 601M | 751M | 559M | 532M |
| Total Assets | 10.4B | 11.0B | 10.8B | 9.6B | 8.5B |
| Total Liabilities | 5.3B | 6.2B | 6.0B | 5.3B | 5.6B |
| Shareholder Equity | — | — | — | — | — |
| Total Debt | 3.7B | 4.1B | 4.1B | 3.6B | 3.6B |
| Net Debt | — | — | — | — | — |
Cash flow positioning
2026 Full Year
Operating Cash Flow
1.1B
-374.8% YoY
Capital Expenditures
—
Free Cash Flow
145M
-40.7% YoY
Key ratios
Gross Margin
35.1%
Operating Margin
5.9%
Net Margin
-33.5%
ROE
-35.2%
Debt / Equity
1.35x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.